86
Participants
Start Date
March 1, 2018
Primary Completion Date
November 20, 2018
Study Completion Date
May 29, 2020
B/F/TAF
50/200/25 mg FDC tablet administered orally once daily without regard to food.
CHU Saint-Pierre, Brussels
CHU de Nice, Nice
Hospital Universitari Germans Trias i Pujol, Badalona
UZ Gent, Ghent
Hopital Europeen Marseille, Marseille
ASST - Fatebenefratelli Sacco, Milan
ASST Papa Giovanni XXIII, Bergamo
Hospital General Universitario Gregorio Maranon, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Hospital Costa Del Sol, Marbella
Interne et Maladies infectieuses, Pessac
Hopital Saint-Andre, Bordeaux
C.H.U. de Nantes - Hotel Dieu, Nantes
CH de Tourcoing, Tourcoing
P.O. Spirito Santo - U.O. Malattie Infettive e Tropicali, Pescara
Hopital Necker - Enfants Malades, Paris
Hopital Saint Louis, Paris
Hopital Saint Antoine, Paris
IRCCS Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Roma
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Clinic de Barcelona, Barcelona
Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
Lead Sponsor
Gilead Sciences
INDUSTRY